Founded in 2010, VRL has become a reference laboratory solely focused on donor eligibility testing and
\nmicrobiology testing for the transplant and medical communities. The company offers a broad menu of
\ninfectious disease screening assays to support the FDA\u2019s 21 CFR 12711 donor eligibility determination
\ntesting requirements, specifically for eye, tissue, organ, stem cell and cord blood, as well as
\nreproductive tissues. VRL employs a total of 60 staff across its main facility in Denver CO, and its
\nsatellite laboratories in Boston, MA, Dallas, TX, and Atlanta, GA.<\/p>\n
The acquisition of VRL reinforces Eurofins\u2019 footprint in specialty clinical testing services and
\nconsolidates the Group\u2019s leadership in the transplantation testing market. Furthermore, VRL\u2019s
\nmicrobiology testing services expands Eurofins\u2019 testing portfolio and increases client penetration in the
\ntransplantation testing market. In return, VRL will have access to the Group\u2019s clients and competencies,
\nas well as its laboratory network infrastructure, which should support its further development.<\/p>\n
Comment from Dr. Gilles Martin, Eurofins CEO: \u201cThe acquisition of VRL is another demonstration of Eurofins Scientific (EUFI.PA), a global leader in bio-analytical testing, and one of the world leaders in genomic services, announces the acquisition of VRL Laboratories (\u201cVRL\u201d), one of the leading laboratories in pre-transplant testing for the eligibility determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\/Ps) in the US.<\/p>\n","protected":false},"author":20,"featured_media":55397,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1601],"tags":[1671,1888,1437,2082,2035,1702],"_links":{"self":[{"href":"http:\/\/beta.next-finance.net\/en\/wp-json\/wp\/v2\/posts\/55399"}],"collection":[{"href":"http:\/\/beta.next-finance.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/beta.next-finance.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/beta.next-finance.net\/en\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"http:\/\/beta.next-finance.net\/en\/wp-json\/wp\/v2\/comments?post=55399"}],"version-history":[{"count":0,"href":"http:\/\/beta.next-finance.net\/en\/wp-json\/wp\/v2\/posts\/55399\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/beta.next-finance.net\/en\/wp-json\/wp\/v2\/media\/55397"}],"wp:attachment":[{"href":"http:\/\/beta.next-finance.net\/en\/wp-json\/wp\/v2\/media?parent=55399"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/beta.next-finance.net\/en\/wp-json\/wp\/v2\/categories?post=55399"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/beta.next-finance.net\/en\/wp-json\/wp\/v2\/tags?post=55399"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nour strategy of expanding and strengthening our network of competence centers. In combination with
\nViraCor and Diatherix, VRL reinforces the Group\u2019s footprint in the testing market for transplantation and
\ninfectious diseases.<\/em>\u201d <\/p>\n","protected":false},"excerpt":{"rendered":"